The efficacy and safety of biopharmaceutical products, combined with their ability to address previously untreatable conditions plays a pivotal role in the survival of people affected by genetic disorders and diseases. As a part of our core strategy, we are developing biosimilars and improved biologics for the treatment of metabolic disorders.